Tandem Diabetes Care (TNDM) Competitors

iRhythm Technologies (NASDAQ:IRTC) and Tandem Diabetes Care (NASDAQ:TNDM) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Is IRTC or TNDM more profitable?

Tandem Diabetes Care has a net margin of -18.37% compared to Tandem Diabetes Care's net margin of -25.33%. iRhythm Technologies' return on equity of -34.38% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-25.33%	-69.87%	-23.50%
Tandem Diabetes Care	-18.37%	-34.38%	-10.91%

Which has higher valuation and earnings, IRTC or TNDM?

iRhythm Technologies has higher earnings, but lower revenue than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$492.68M	6.04	-$123.41M	-$4.23	-22.61
Tandem Diabetes Care	$747.72M	4.22	-$222.61M	-$2.17	-22.51

Which has more risk and volatility, IRTC or TNDM?

iRhythm Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Does the MarketBeat Community believe in IRTC or TNDM?

Tandem Diabetes Care received 183 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.04% of users gave iRhythm Technologies an outperform vote while only 61.18% of users gave Tandem Diabetes Care an outperform vote.

Company	Underperform	Outperform
iRhythm Technologies	Outperform Votes 389 66.04%	Underperform Votes 200 33.96%
Tandem Diabetes Care	Outperform Votes 572 61.18%	Underperform Votes 363 38.82%

Do analysts rate IRTC or TNDM?

iRhythm Technologies currently has a consensus price target of $133.25, indicating a potential upside of 39.30%. Tandem Diabetes Care has a consensus price target of $50.58, indicating a potential upside of 3.55%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, equities research analysts plainly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tandem Diabetes Care	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Does the media refer more to IRTC or TNDM?

In the previous week, iRhythm Technologies had 6 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 14 mentions for iRhythm Technologies and 8 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 0.84 beat iRhythm Technologies' score of 0.81 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tandem Diabetes Care beats iRhythm Technologies on 9 of the 16 factors compared between the two stocks.